News und Analysen
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions
Agilent Awards Octagon Therapeutics with a Golden Ticket at LabCentral
Agilent Technologies Inc. (NYSE: A) announces that Octagon Therapeutics has been awarded an Agilent Golden Ticket at LabCentral. The Golden Ticket was presented to Octagon during a virtual online
Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the second quarter of fiscal year 2021, the period ended February 28, 2021, after the close of
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk
Acadia Healthcare Forms Joint Venture with Lutheran Health Network of Indiana, LLC to Build Modern Behavioral Health Facility to Serve Fort Wayne Area Communities
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Lutheran Health Network of Indiana, LLC, one of Indiana’s premier, integrated healthcare
LivaNova to Host Conference Call for First Quarter 2021 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2021 results on Wednesday, April 28, 2021 at 12 p.m
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the virtual Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare
Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer
Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in combination with letrozole was
Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer
Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in combination with letrozole was
The Humana Foundation Awards Nearly $1 Million in a Second Year Investment to Kingsley House and Growing Local Food Collaborative
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, announces its second year of investments, totaling nearly $1 million in two local projects in the greater
Epic and Humana Deliver on Commitment to Enhance Connectivity and Collaboration Among Patients, Providers, and Health Plans
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Epic, developer of the nation’s most widely used comprehensive health record, have completed the first stage of a joint effort
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the
Humana Adds H Mart to List of National Retailers for Healthy Foods Card Benefit
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies and H Mart, the largest Asian supermarket chain in the U.S., announced today a collaboration to combat food
Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2021. The purpose of
Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2021. The purpose of
Dexcom Promotes Jereme Sylvain to Chief Financial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Jereme Sylvain to the role of Executive Vice President and Chief
Dexcom Promotes Jereme Sylvain to Chief Financial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Jereme Sylvain to the role of Executive Vice President and Chief
Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place today in an oral presentation at
Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its support for the
Illumina Announces Board Changes
Illumina, Inc. (NASDAQ: ILMN) (the “Company”) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company’s new Chair
Illumina Announces Board Changes
Illumina, Inc. (NASDAQ: ILMN) (the “Company”) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company’s new Chair
Illumina Announces Board Changes
Illumina, Inc. (NASDAQ: ILMN) (the “Company”) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company’s new Chair